可溶性鸟苷酸环化酶激动剂维利西呱在心力衰竭治疗中的研究进展
Clinical research progress of soluble guanylate cyclase stimulator Vericiguat in heart failure
赵烊烊 1彭杰成2
作者信息
- 1. 安徽医科大学附属安庆第一人民医院心内科(安徽安庆,246003);安徽医科大学第五临床医学院
- 2. 安徽医科大学附属安庆第一人民医院心内科(安徽安庆,246003)
- 折叠
摘要
心力衰竭(heart failure,HF)是心血管疾病发展的终末结局和心血管疾病患者最主要的死亡原因.近年来,随着进一步的研究,HF的治疗正在不断完善,然而HF患者的高住院率和高病死率在目前依旧是一大难题,其生活质量和预后仍处于较低水平.而维利西呱作为一种可溶性鸟苷酸环化酶激动剂,以其独特的作用机制和良好的安全性、耐受性为HF治疗提供了新思路,可谓潜力巨大.本文就维利西呱的作用通路、安全性、耐受性方面以及目前相关临床研究进展进行综述.
Abstract
Heart failure(HF)is the final outcome of cardiovascular disease development and the main cause of death in patients with cardiovascular disease.In recent years,with further in-depth research,the treatment of HF is constantly improving.However,the high hospitalization rate and high mortality rate of HF patients are still a major problem,and their quality of life and prognosis are still at a low level.As a soluble guanylate cyclase stimulator,vericiguat provides new ideas for the treatment of HF with its unique mechanism of action,good safe-ty and tolerability,which has great potential.In this paper,we reviewed the pathways,safety and tolerability of vericiguat and the current clinical research progress.
关键词
维利西呱/心力衰竭/可溶性鸟苷酸环化酶激动剂/一氧化氮-可溶性鸟苷酸环化酶-环磷酸鸟苷信号途径Key words
vericiguat/heart failure/soluble guanylate cyclase stimulator/nitric oxide-soluble guanylate cy-clase-cyclic guanosine monophosphate signaling pathway引用本文复制引用
基金项目
安徽省卫生健康委项目(AHWJ2021b103)
出版年
2024
NETL
NSTL
万方数据